• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Predictions for the next 30 days

Quote
















anonymous said:
Ha, total bullshit. You can’t target a demographic you fucking idiot.
Click to expand...
I went thru this at Sanofi. They offer early retirement packages in hopes that some of the people will accept and fewer people will have to be cut involuntarily. Allergan already knows the headcount that they need to payoff. If you take a package then you could be saving the job of a younger, less invested employee. I have never seen a person submit for an early retirement package and not be accepted for it. That is most likely legal jargon.
 












anonymous said:
An early retirement initiative will be offered to employees with 15+ years of service. If we refuse to accept the offer, then we will lose the opportunity to accept it later if we lose our job when the wave of cuts go in to effect. Good luck!
Click to expand...

Bullshit. That would be a move by a company that gives at least half a fuck. The clowns running this shit show into the ground GIVE ZERO FUCKS!
 




Tomorrow's town hall will start with Bill Merry reaching into the chest of BS and pulling out his still beating heart. He will offer it up to the Board of Directors who will nod and bless his ascendency to CEO. There will be a few sacrifices to the Gods of Investing, probably that dude who holds the iPad and takes questions, but other than that it should be uneventful.
 
















anonymous said:
To be expected after all shareholders with tax loss harvesting finished up last Friday. The real question becomes, can Allergan gain any ground back into the low $200's.
Click to expand...

Possibly. Keep an eye on the institutional investors and watch. I'm optimistic on that target.

When are fourth quarter earnings due to be released?
 








anonymous said:
Possibly. Keep an eye on the institutional investors and watch. I'm optimistic on that target.

When are fourth quarter earnings due to be released?
Click to expand...



I believe Feb 6th is the next earnings call. 25% gain almost gets AGN back to the price paid by Actavis (excluding the cash component to shareholders on record at time of the sale) $205. Not likely to see 35-40% ($221) unless earnings hit, phase 3's look amazing, appeal gets reversed, moon aligns with mars, birds fly out of my ass, etc.
 
























Top Bottom
Back
Quote